• Je něco špatně v tomto záznamu ?

Cellular Delivery of Bioorthogonal Pretargeting Therapeutics in PSMA-Positive Prostate Cancer

S. Hapuarachchige, CT. Huang, MC. Donnelly, C. Bařinka, SE. Lupold, MG. Pomper, D. Artemov,

. 2020 ; 17 (1) : 98-108. [pub] 20191216

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, Research Support, N.I.H., Extramural, práce podpořená grantem, Research Support, U.S. Gov't, Non-P.H.S.

Perzistentní odkaz   https://www.medvik.cz/link/bmc20028615

Grantová podpora
R01 CA209884 NCI NIH HHS - United States

Prostate cancer is primarily fatal after it becomes metastatic and castration-resistant despite novel combined hormonal and chemotherapeutic regimens. Hence, new therapeutic concepts and drug delivery strategies are urgently needed for the eradication of this devastating disease. Here we report the highly specific, in situ click chemistry driven pretargeted delivery of cytotoxic drug carriers to PSMA(+) prostate cancer cells. Anti-PSMA 5D3 mAb and its F(ab')2 fragments were functionalized with trans-cyclooctene (TCO), labeled with a fluorophore, and used as pretargeting components. Human serum albumin (ALB) was loaded with the DM1 antitubulin agent, functionalized with PEGylated tetrazine (PEG4-Tz), labeled with a fluorophore, and used as the drug delivery component. The internalization kinetics of components and the therapeutic efficacy of the pretargeted click therapy were studied in PSMA(+) PC3-PIP and PSMA(-) PC3-Flu control cells. The F(ab')2 fragments were internalized faster than 5D3 mAb in PSMA(+) PC3-PIP cells. In the two-component pretargeted imaging study, both components were colocalized in a perinuclear location of the cytoplasm of PC3-PIP cells. Better colocalization was achieved when 5D3 mAb was used as the pretargeting component. Consecutively, the in vitro cell viability study shows a significantly higher therapeutic effect of click therapy in PC3-PIP cells when 5D3 mAb was used for pretargeting, compared to its F(ab')2 derivative. 5D3 mAb has a longer lifetime on the cell surface, when compared to its F(ab')2 analogue, enabling efficient cross-linking with the drug delivery component and increased efficacy. Pretargeting and drug delivery components were cross-linked via multiple bioorthogonal click chemistry reactions on the surface of PSMA(+) PC cells forming nanoclusters, which undergo fast cellular internalization and intracellular transport to perinuclear locations.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20028615
003      
CZ-PrNML
005      
20210114154447.0
007      
ta
008      
210105s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1021/acs.molpharmaceut.9b00788 $2 doi
035    __
$a (PubMed)31840521
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Hapuarachchige, Sudath $u The Russell H. Morgan Department of Radiology and Radiological Science , The Johns Hopkins University School of Medicine , 720 Rutland Avenue , Baltimore , Maryland 21205 , United States.
245    10
$a Cellular Delivery of Bioorthogonal Pretargeting Therapeutics in PSMA-Positive Prostate Cancer / $c S. Hapuarachchige, CT. Huang, MC. Donnelly, C. Bařinka, SE. Lupold, MG. Pomper, D. Artemov,
520    9_
$a Prostate cancer is primarily fatal after it becomes metastatic and castration-resistant despite novel combined hormonal and chemotherapeutic regimens. Hence, new therapeutic concepts and drug delivery strategies are urgently needed for the eradication of this devastating disease. Here we report the highly specific, in situ click chemistry driven pretargeted delivery of cytotoxic drug carriers to PSMA(+) prostate cancer cells. Anti-PSMA 5D3 mAb and its F(ab')2 fragments were functionalized with trans-cyclooctene (TCO), labeled with a fluorophore, and used as pretargeting components. Human serum albumin (ALB) was loaded with the DM1 antitubulin agent, functionalized with PEGylated tetrazine (PEG4-Tz), labeled with a fluorophore, and used as the drug delivery component. The internalization kinetics of components and the therapeutic efficacy of the pretargeted click therapy were studied in PSMA(+) PC3-PIP and PSMA(-) PC3-Flu control cells. The F(ab')2 fragments were internalized faster than 5D3 mAb in PSMA(+) PC3-PIP cells. In the two-component pretargeted imaging study, both components were colocalized in a perinuclear location of the cytoplasm of PC3-PIP cells. Better colocalization was achieved when 5D3 mAb was used as the pretargeting component. Consecutively, the in vitro cell viability study shows a significantly higher therapeutic effect of click therapy in PC3-PIP cells when 5D3 mAb was used for pretargeting, compared to its F(ab')2 derivative. 5D3 mAb has a longer lifetime on the cell surface, when compared to its F(ab')2 analogue, enabling efficient cross-linking with the drug delivery component and increased efficacy. Pretargeting and drug delivery components were cross-linked via multiple bioorthogonal click chemistry reactions on the surface of PSMA(+) PC cells forming nanoclusters, which undergo fast cellular internalization and intracellular transport to perinuclear locations.
650    _2
$a albuminy $7 D000418
650    _2
$a monoklonální protilátky $x chemie $x metabolismus $x terapeutické užití $7 D000911
650    _2
$a antigeny povrchové $x imunologie $7 D000954
650    _2
$a fytogenní protinádorové látky $x terapeutické užití $7 D000972
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a viabilita buněk $x účinky léků $7 D002470
650    _2
$a click chemie $x metody $7 D057930
650    _2
$a cyklooktany $x chemie $7 D034242
650    _2
$a lékové transportní systémy $x metody $7 D016503
650    _2
$a fluorbenzeny $x chemie $7 D005464
650    _2
$a glutamátkarboxypeptidasa II $x imunologie $x metabolismus $7 D043425
650    _2
$a lidé $7 D006801
650    _2
$a imunoglobuliny - Fab fragmenty $x chemie $x metabolismus $x terapeutické užití $7 D007140
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a maytansin $x terapeutické užití $7 D008453
650    _2
$a nanomedicína $7 D050997
650    _2
$a nádory prostaty $x farmakoterapie $x enzymologie $x metabolismus $7 D011471
650    _2
$a modulátory tubulinu $x terapeutické užití $7 D050257
655    _2
$a časopisecké články $7 D016428
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a Research Support, U.S. Gov't, Non-P.H.S. $7 D013486
700    1_
$a Huang, Colin T $u The Russell H. Morgan Department of Radiology and Radiological Science , The Johns Hopkins University School of Medicine , 720 Rutland Avenue , Baltimore , Maryland 21205 , United States.
700    1_
$a Donnelly, Madeline C $u The Russell H. Morgan Department of Radiology and Radiological Science , The Johns Hopkins University School of Medicine , 720 Rutland Avenue , Baltimore , Maryland 21205 , United States.
700    1_
$a Bařinka, Cyril $u Laboratory of Structural Biology , Institute of Biotechnology of the Czech Academy of Sciences , Prumyslova 595 , Vestec 252 50 , Czech Republic.
700    1_
$a Lupold, Shawn E $u The James Buchanan Brady Urologic Institute and Department of Urology , Johns Hopkins School of Medicine , 600 N. Wolfe St. , Baltimore , Maryland 21287 , United States.
700    1_
$a Pomper, Martin G $u The Russell H. Morgan Department of Radiology and Radiological Science , The Johns Hopkins University School of Medicine , 720 Rutland Avenue , Baltimore , Maryland 21205 , United States. The James Buchanan Brady Urologic Institute and Department of Urology , Johns Hopkins School of Medicine , 600 N. Wolfe St. , Baltimore , Maryland 21287 , United States. Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center , The Johns Hopkins University School of Medicine , 401 N. Broadway , Baltimore , Maryland 21231 , United States.
700    1_
$a Artemov, Dmitri $u The Russell H. Morgan Department of Radiology and Radiological Science , The Johns Hopkins University School of Medicine , 720 Rutland Avenue , Baltimore , Maryland 21205 , United States. Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center , The Johns Hopkins University School of Medicine , 401 N. Broadway , Baltimore , Maryland 21231 , United States.
773    0_
$w MED00008279 $t Molecular pharmaceutics $x 1543-8392 $g Roč. 17, č. 1 (2020), s. 98-108
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31840521 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20210105 $b ABA008
991    __
$a 20210114154444 $b ABA008
999    __
$a ok $b bmc $g 1608950 $s 1119795
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 17 $c 1 $d 98-108 $e 20191216 $i 1543-8392 $m Molecular pharmaceutics $n Mol Pharm $x MED00008279
GRA    __
$a R01 CA209884 $p NCI NIH HHS $2 United States
LZP    __
$a Pubmed-20210105

Najít záznam

Citační ukazatele

Nahrávání dat ...

    Možnosti archivace